Tomohiro Fujii
ADC Researcher Ajinomoto Bio-Pharma Services
Seminars
Wednesday 5th November 2025
A Versatile Approach to Generating Next-Generation Antibody Conjugates Through AJICAP® Technologies
4:30 pm
- AJICAP Conjugation: Leveraging site-specific Technologies in next-generation ADCs to enhance clinically relevant biological properties through precise DAR control such as 1, 2, 4, 8 and higherÂ
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and enables versatile synthesis of ADCs with higher DAR numbers, even with highly hydrophilic payloads
- Application for new modality conjugates: Bispecific antibodies and AOCs produced by fully chemical conjugation technology
